
How we made ARDS risk readable at a glance for ICU clinicians
Bayer was building ICU Angel, a risk-monitoring platform paired with a drug intervention for ARDS. Clinicians and principal investigators needed to follow a patient's progression and medication response without digging through screens. We designed both views and ran moderated prototype testing across the whole workflow before anything was built. Clinicians went from about 30 seconds to less than 5 seconds to spot a critical change, and the platform went into a pilot.
Piloted

